Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitomycin C + epirubicin + cisplatin + 5-fluorouracil + leucovorin
- Development stage
- Phase 3
- Lead developer
- Kyowa Kirin
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of five agents: mitomycin C, epirubicin, cisplatin, 5-fluorouracil (5-FU), and leucovorin. Each component has a distinct mechanism of action targeting cancer cells through different pathways: - **Mitomycin C** is an alkylating agent that crosslinks DNA, inhibiting DNA synthesis and function. - **Epirubicin** is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks. - **Cisplatin** forms platinum-DNA adducts causing crosslinking and apoptosis. - **5-Fluorouracil (5-FU)** is a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis. - **Leucovorin** enhances the binding of 5-FU to thymidylate synthase, increasing its cytotoxicity. This regimen (sometimes referred to as MEPFL) has been studied as induction chemotherapy for advanced nasopharyngeal carcinoma[2] and in other gastrointestinal cancers. The combination aims to maximize antitumor efficacy by attacking cancer cells via multiple mechanisms.
- Other names
- MEPFL
02
Targets
DNATS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on mitomycin C + epirubicin + cisplatin + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitomycin C + epirubicin + cisplatin + 5-fluorouracil + leucovorin.